Sydney Stewart, Author at BioTuesdays

Developments

La Jolla Pharma reports interim results from Phase 2 hemochromatosis trial

La Jolla Pharmaceutical (NASDAQ:LJPC) reported results from a pre-specified interim analysis of its Phase 2 study of LJPC-401 in patients with hereditary hemochromatosis (HH).

June 6, 2019

Executive Moves

Canopy Growth’s medical division names Dr. Marcel Bonn-Miller as global clinical scientific director

Spectrum Therapeutics, the medical division of Canopy Growth (TSX:WEED; NYSE:CGC) appointed Dr. Marcel Bonn-Miller as global clinical scientific director.

June 5, 2019

Developments

Aimmune reports new Phase 3 data for peanut allergy immunotherapeutic

Aimmune Therapeutics (NASDAQ:AIMT) reported new data from a Phase 3 study of AR101, which delivers a daily dose of peanut protein, as a treatment to reduce the frequency and severity of allergic reactions to peanuts...

June 4, 2019

Markets

Analysts start Trevi Therapeutics at OP, buy; PTs $14, $20

SVB Leerink launched coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $14 price target. The stock closed at $9.99 on May 31.

June 4, 2019

Developments

Zenabis receives hemp production license from Health Canada

Zenabis Global (TSX:ZENA) received an industrial hemp production license from Health Canada. “This is the second cultivation license we have received from Health Canada this year, and is another important step...

June 3, 2019

Developments

REGENXBIO completes dosing for Phase 1/2a wet AMD trial

REGENXBIO (NASDAQ:RGNX) has completed dosing in its Phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). RGX-314 uses REGENXBIO’s proprietary NAV gene delivery platform to...

May 31, 2019

Developments

BriaCell technology and clinical data published at the 2019 ASCO

BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...

May 31, 2019

Markets

Canaccord starts TransMedics at buy; PT $37

Canaccord Genuity initiated coverage of TransMedics Group (NASDAQ:TMDX) with a “buy” rating and price target of $37. The stock closed at $28.88 on May 24.

May 28, 2019

Developments

Zenabis graduates to the TSX

Zenabis Global Inc. (TSXV:ZENA) received approval to list its common shares and outstanding listed common share purchase warrants on the TSX.

May 24, 2019

Developments

Canopy Growth acquires skincare and well-being company, This Works

Canopy Growth (TSX:WEED; NYSE: CGC) acquired This Works in an all-cash transaction for £43 million. British-based This Works offers a range of high-quality natural skincare and sleep solution products, including deep...

May 22, 2019

Author - Sydney Stewart

La Jolla Pharma reports interim results from Phase 2 hemochromatosis trial

Canopy Growth’s medical division names Dr. Marcel Bonn-Miller as global clinical scientific director

Aimmune reports new Phase 3 data for peanut allergy immunotherapeutic

Analysts start Trevi Therapeutics at OP, buy; PTs $14, $20

Zenabis receives hemp production license from Health Canada

REGENXBIO completes dosing for Phase 1/2a wet AMD trial

BriaCell technology and clinical data published at the 2019 ASCO

Canaccord starts TransMedics at buy; PT $37

Zenabis graduates to the TSX

Canopy Growth acquires skincare and well-being company, This Works

Subscribe